Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

OnlineFirst

March 05, 2021

  • Small Molecule Therapeutics
    Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
    Shogo Shigeta, Goldie Y. L. Lui, Reid Shaw, Russell Moser, Kay E. Gurley, Grace Durenberger, Rachele Rosati, Robert L. Diaz, Tan A. Ince, Elizabeth M. Swisher, Carla Grandori and Christopher J. Kemp
    Mol Cancer Ther March 5 2021 DOI:10.1158/1535-7163.MCT-20-0809

  • Cancer Biology and Translational Studies | AuthorChoice
    V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer
    Bradleigh Whitton, Haruko Okamoto, Matthew Rose-Zerilli, Graham Packham and Simon J. Crabb
    Mol Cancer Ther March 5 2021 DOI:10.1158/1535-7163.MCT-20-0662

March 03, 2021

  • Research Article | AUTHOR MANUSCRIPT
    The monoacylglycerol lipase inhibitor JZL184 inhibits lung cancer cell invasion and metastasis via the CB1 cannabinoid receptor
    Jan Lukas Prüser, Robert Ramer, Felix Wittig, Igor Ivanov, Jutta Merkord and Burkhard Hinz
    Mol Cancer Ther March 3 2021 DOI:10.1158/1535-7163.MCT-20-0589

March 02, 2021

  • Research Article | AUTHOR MANUSCRIPT
    Robust anti-tumor activity and low cytokine production by novel humanized anti-CD19 CAR-T cells
    Alka Dwivedi, Atharva Karulkar, Sarbari Ghosh, Srisathya Srinivasan, Bajarang Vasant Kumbhar, Ankesh Kumar Jaiswal, Atish Kizhakeyil, Sweety Asija, Afrin Rafiq, Sushant Kumar, Albeena Nisar, Deepali Pandit Patil, Minal Vivek Poojary, Hasmukh Jain, Shripad D Banavali, Steven L Highfill, David F Stroncek, Nirali N Shah, Terry J Fry, Gaurav Narula and Rahul Purwar
    Mol Cancer Ther March 2 2021 DOI:10.1158/1535-7163.MCT-20-0476

March 01, 2021

  • Research Article | AuthorChoice | AUTHOR MANUSCRIPT
    Discovery of JNJ-63576253, a next-generation androgen receptor antagonist active against wild-type and clinically-relevant ligand binding domain mutations in mCRPC
    Jonathan R. Branch, Tammy L. Bush, Vineet Pande, Peter J Connolly, Zhuming Zhang, Ian Hickson, Janine Ondrus, Steffen Jaensch, James R. Bischoff, Georges Habineza, Geert Van Hecke, Lieven Meerpoel, Kathryn Packman, Christopher J. Parrett, Yolanda T. Chong, Marco M. Gottardis and Gilles Bignan
    Mol Cancer Ther March 1 2021 DOI:10.1158/1535-7163.MCT-20-0510

  • Research Article | AUTHOR MANUSCRIPT
    Phenotypic models of CAR-T cell activation elucidate the pivotal regulatory role of CAR down-modulation
    Yoram Reiter, Raanan Greenman, Yoav Pizam, Maya Haus-Cohen, Guy Horev, Galit Denkberg, Shai Shen-Orr and Jacob Rubinstein
    Mol Cancer Ther March 1 2021 DOI:10.1158/1535-7163.MCT-19-1110

  • Research Article | AUTHOR MANUSCRIPT
    The discovery of a novel anti-metastatic Bcl3 inhibitor
    Jitka Soukupová, Cinzia Bordoni, Daniel J Turnham, William W Yang, Gillian Seaton, Aleksandra Gruca, Rhiannon French, Kok Yung Lee, Athina Varnava, Luke Piggott, Richard W. E. Clarkson, Andrew D Westwell and Andrea Brancale
    Mol Cancer Ther March 1 2021 DOI:10.1158/1535-7163.MCT-20-0283

  • Research Article | AUTHOR MANUSCRIPT
    Shaping Functional Avidity of CAR-T Cells: Affinity, Avidity and Antigen Density that Regulate Response
    Raanan Greenman, Yoav Pizam, Maya Haus-Cohen, Alona Goor, Guy Horev, Galit Denkberg, Keren Sinik, Yael Elbaz, Vered Bronner, Anat Globerson Levin, Galit Horn, Shai Shen-Orr and Yoram Reiter
    Mol Cancer Ther March 1 2021 DOI:10.1158/1535-7163.MCT-19-1109

  • Research Article | AuthorChoice | AUTHOR MANUSCRIPT
    TARGETING EYA3 IN EWING SARCOMA RETARDS TUMOR GROWTH AND ANGIOGENESIS
    Yuhua Wang, Ram Naresh Pandey, Kaushik Roychoudhury, David Milewski, Tanya V. Kalin, Sara Szabo, Joseph G Pressey and Rashmi S Hegde
    Mol Cancer Ther March 1 2021 DOI:10.1158/1535-7163.MCT-20-0749

February 25, 2021

  • Research Article | AUTHOR MANUSCRIPT
    Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma
    Yongmei Feng, Gaurav Pathria, Susanne Heynen-Genel, Michael R Jackson, Brian James, Jun Yin, David A. Scott and Ze'ev A Ronai
    Mol Cancer Ther February 25 2021 DOI:10.1158/1535-7163.MCT-20-0354

  • Research Article | AuthorChoice | AUTHOR MANUSCRIPT
    Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress
    Korie A. Grayson, Jacob M. Hope, Wenjun Wang, Cynthia A. Reinhart-King and Michael R King
    Mol Cancer Ther February 25 2021 DOI:10.1158/1535-7163.MCT-20-0495

  • Research Article | AUTHOR MANUSCRIPT
    A novel antibody-interleukin-15 fusion protein selectively localizes to tumors, synergizes with TNF-based immunocytokine and inhibits metastasis
    Riccardo Corbellari, Marco Stringhini, Jacqueline Mock, Tiziano Ongaro, Alessandra Villa, Dario Neri and Roberto De Luca
    Mol Cancer Ther February 25 2021 DOI:10.1158/1535-7163.MCT-20-0853

  • Research Article | AUTHOR MANUSCRIPT
    Preclinical Assessment of AMG 596, a BiTE® (Bispecific T-Cell Engager) Immune Therapy Targeting the Tumor-Specific Antigen EGFRvIII
    Alexander Sternjak, Fei Lee, Oliver Thomas, Mercedesz Balazs, Joachim Wahl, Grit Lorenczewski, Ines Ullrich, Markus Muenz, Benno Rattel, Julie M. Ballis and Matthias Friedrich
    Mol Cancer Ther February 25 2021 DOI:10.1158/1535-7163.MCT-20-0508

  • Research Article | AUTHOR MANUSCRIPT
    PGE2 released by pancreatic cancer cells undergoing ER stress transfers the stress to DCs impairing their immune function.
    Mara Cirone, Maria Saveria Gilardini Montani, Rossella Benedetti, Silvia Piconese, Fabio Maria Pulcinelli, Anna Maria Timperio, Maria Anele Romeo, Gabriella D'Orazi, Laura Masuelli, Maurizio Mattei and Roberto Bei
    Mol Cancer Ther February 25 2021 DOI:10.1158/1535-7163.MCT-20-0699

  • Research Article | AUTHOR MANUSCRIPT
    Anti-tumor activity of NLG207 (formerly CRLX101) in combination with enzalutamide in preclinical prostate cancer models
    Keith T Schmidt, Cindy H. Chau, Jonathan D. Strope, Alwin D.R. Huitema, Tristan M Sissung, Douglas K Price and William D. Figg
    Mol Cancer Ther February 25 2021 DOI:10.1158/1535-7163.MCT-20-0228

February 10, 2021

  • Research Article | AUTHOR MANUSCRIPT
    PP2A-activating drugs enhance FLT3 inhibitor efficacy through AKT inhibition-dependent GSK-3β-mediated c-Myc and Pim-1 proteasomal degradation
    Mario Scarpa, Prerna Singh, Christopher M Bailey, Jonelle K. Lee, Shivani Kapoor, Rena G. Lapidus, Sandrine Niyongere, Jaya Sangodkar, Yin Wang, Danilo Perrotti, Goutham Narla and Maria R. Baer
    Mol Cancer Ther February 10 2021 DOI:10.1158/1535-7163.MCT-20-0663

February 09, 2021

  • Research Article | AUTHOR MANUSCRIPT
    Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK
    John M. Mariadason, David K Lau, Ian Y Luk, Laura J. Jenkins, Andrew Martin, David S. Williams, Kael L Schoffer, Fiona Chionh, Michael Buchert, Katrin Sjoquist, Alex Boussioutas, Sarah A Hayes, Matthias Ernst, Andrew J Weickhardt, Nick Pavlakis and Niall C Tebbutt
    Mol Cancer Ther February 9 2021 DOI:10.1158/1535-7163.MCT-20-0836

February 05, 2021

  • Research Article | AUTHOR MANUSCRIPT
    Anti-LYPD1/CD3 T cell dependent bispecific antibody for the treatment of ovarian cancer
    Teemu T Junttila, Daniel Bravo-Perez, Amy A Lo, Wei-Ching Liang, James Ziai, Thinh Pham, Diego Ellerman, Yan Wu, Ji Li, Jennifer Johnston, Hao Cai, Meric Ovacik, C. Andrew Boswell, Danielle Mandikian, Klara Totpal, Maria Hristopoulos, Robyn Clark, Elaine Mai, Dionysos Slaga, Kathy Hötzel, Genee Lee, Debra Dunlap, Jian Payandeh and Dorothee Nickles
    Mol Cancer Ther February 5 2021 DOI:10.1158/1535-7163.MCT-20-0490

February 03, 2021

  • Research Article | AUTHOR MANUSCRIPT
    Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
    Elizabeth A Wilson, Nahid Sultana, Khyati N. Shah, Howard L. Elford and Jesika S. Faridi
    Mol Cancer Ther February 3 2021 DOI:10.1158/1535-7163.MCT-20-0373

  • Research Article | AuthorChoice | AUTHOR MANUSCRIPT
    Isoform- and phosphorylation-specific multiplexed quantitative pharmacodynamics of drugs targeting PI3K and MAPK signaling in xenograft models and clinical biopsies
    William G. Herrick, Casey L. Kilpatrick, Melinda G. Hollingshead, Dominic Esposito, Geraldine O'Sullivan Coyne, Andrea M. Gross, Barry C. Johnson, Alice P Chen, Brigitte C. Widemann, James H. Doroshow, Ralph E Parchment and Apurva K Srivastava
    Mol Cancer Ther February 3 2021 DOI:10.1158/1535-7163.MCT-20-0566

  • Research Article | AUTHOR MANUSCRIPT
    Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-L-glutamic acid-coated Layer-by-Layer Nanoparticles
    Isidora Tošić, Lisa N Heppler, Susana P. Egusquiaguirre, Natalie Boehnke, Santiago Correa, Daniel F. Costa, Elizabeth A. Grossman Moore, Sharmistha Pal, Douglas S Richardson, Alexander R Ivanov, Daphne A Haas-Kogan, Daniel K. Nomura, Paula T Hammond and David A. Frank
    Mol Cancer Ther February 3 2021 DOI:10.1158/1535-7163.MCT-20-0505

  • Research Article | AUTHOR MANUSCRIPT
    ONC201 shows anti-cancer activity against medullary thyroid cancer via transcriptional inhibition of RET, VEGFR2, and IGFBP2
    Rozita Bagheri-Yarmand, Ramona Dadu, Lei Ye, Yaashmin S. Jebaraj, Jade A Martinez, Junsheng Ma, Rohinton S. Tarapore, Joshua E Allen, Steven I. Sherman, Michelle D. Williams and Robert F Gagel
    Mol Cancer Ther February 3 2021 DOI:10.1158/1535-7163.MCT-20-0386

  • Research Article | AUTHOR MANUSCRIPT
    ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer
    Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C. Gokhale, Hong L Tiv, Aine R Knott, Margaret K Wilkens, Kara M Soroko, Mika Lin, Chiara Ambrogio, Monica Musteanu, Atsuko Ogino, Jihyun Choi, Magda Bahcall, Arrien A. Bertram, Emily S Chambers, Cloud P. Paweletz, Shripad V Bhagwat, Jason R Manro, Ramon V Tiu and Pasi A Janne
    Mol Cancer Ther February 3 2021 DOI:10.1158/1535-7163.MCT-20-0531

January 05, 2021

  • Subject Review | AUTHOR MANUSCRIPT
    Role of polo-like kinase 4 (PLK4) in epithelial cancers and recent progress in its small molecule targeting for cancer management
    Debra R. Garvey, Gagan Chhabra, Mary A. Ndiaye and Nihal Ahmad
    Mol Cancer Ther January 5 2021 DOI:10.1158/1535-7163.MCT-20-0741

View by section

OnlineFirst articles are published online before they appear in a regular issue of the journal. Molecular Cancer Therapeutics publishes two types of OnlineFirst articles.

OnlineFirst Author Manuscripts are PDF versions of manuscripts that have been peer reviewed and accepted for publication, but not yet copyedited or typeset, allowing readers the most rapid access to accepted papers. They appear on the OnlineFirst page as submitted by the authors. The Author Manuscript remains on the OnlineFirst page until it is either replaced by the final proof version or when the final version of the paper is published in an online issue.

Please note that while we strive to post all accepted manuscripts within two days of their acceptance, there may be editorial considerations, such as a planned press release or the need to coordinate posting of related articles, which may preclude or delay Author Manuscript posting.

Author Manuscripts are normally replaced on the OnlineFirst page by the final proof version of the article, which incorporates author corrections but is not yet paginated.

When papers are published in an issue, they are removed from the OnlineFirst page and appear in the appropriate issue's table of contents. The date of first publication appears below each title, followed by the article's unique Digital Object Identifier (DOI).

While an article is OnlineFirst, it may be cited as shown in the following example:

Amin DN, Ahuja A, Yaswen, et al. A TORC2-Akt Feedforward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. (October 5, 2015) Mol Cancer Ther, 10.1158/1535-7163.MCT-15-0403.

Sign up to be notified each time OnlineFirst articles are posted in Molecular Cancer Therapeutics.

  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement